Literature DB >> 14635058

Human CD4+CD25+ regulatory cells have marked and sustained effects on CD8+ T cell activation.

Niels Olsen Saraiva Câmara1, Fabien Sebille, Robert I Lechler.   

Abstract

Amongst the many types of regulatory cells that have been described during the past few years, the spontaneously occurring population that is characterized by co-expression of CD4 and CD25 appears to play a key role in the prevention of autoimmunity and the maintenance of transplantation tolerance. In this study we have examined the ability of CD4(+)CD25(+) T cells to regulate human CD8(+) T cells, and the behavior of CD8(+) T cells following activation in the presence of regulatory CD4(+)CD25(+) T cells. The experiments described here demonstrate that human CD4(+)CD25(+) T cells cause pronounced and sustained inhibition of CD8(+) T cell proliferation in response to polyclonal and allogeneic stimulation. The regulation of CD8(+) T cell activation was cell contact-dependent and included inhibition of perforin, granzyme B and IFN-gamma cytokine production at the transcriptional level and impaired cytotoxicity. The regulated CD8(+) T cell population showed sustained hyporesponsiveness and refractoriness to exogenous IL-2. These data provide insights into the short- and long-term effects of CD4(+)CD25(+) T cells on CD8(+) T cells that could be of considerable value in optimizing vaccination against tumor and viral antigens.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14635058     DOI: 10.1002/eji.200323966

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  27 in total

1.  CD4+ CD25+ T cells regulate vaccine-generated primary and memory CD8+ T-cell responses against herpes simplex virus type 1.

Authors:  Felix N Toka; Susmit Suvas; Barry T Rouse
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

Review 2.  Immune modulation of inflammatory conditions: regulatory T cells for treatment of GvHD.

Authors:  Doreen Haase; Mireille Starke; Kia Joo Puan; Tuck Siong Lai; Olaf Rotzschke
Journal:  Immunol Res       Date:  2012-09       Impact factor: 2.829

3.  CD4+ CD25+ but not CD4+ Foxp3+ T cells as a regulatory subset in primary biliary cirrhosis.

Authors:  Dandan Wang; Huayong Zhang; Jun Liang; Zhifeng Gu; Qiang Zhou; Xiangshan Fan; Yayi Hou; Lingyun Sun
Journal:  Cell Mol Immunol       Date:  2010-08-23       Impact factor: 11.530

4.  CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection.

Authors:  Gennadiy Zelinskyy; Shelly J Robertson; Simone Schimmer; Ronald J Messer; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

5.  Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responses.

Authors:  Nadia Alatrakchi; Camilla S Graham; Hans J J van der Vliet; Kenneth E Sherman; Mark A Exley; Margaret James Koziel
Journal:  J Virol       Date:  2007-03-21       Impact factor: 5.103

6.  Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection.

Authors:  Ornella Franzese; Patrick T F Kennedy; Adam J Gehring; Jim Gotto; Roger Williams; Mala K Maini; Antonio Bertoletti
Journal:  J Virol       Date:  2005-03       Impact factor: 5.103

7.  Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.

Authors:  Manuel Nieto-Sampedro; Beatriz Valle-Argos; Diego Gómez-Nicola; Alfonso Fernández-Mayoralas; Manuel Nieto-Díaz
Journal:  Clin Med Insights Oncol       Date:  2011-09-21

8.  Reduced frequency of FOXP3+ CD4+CD25+ regulatory T cells in patients with chronic graft-versus-host disease.

Authors:  Emmanuel Zorn; Haesook T Kim; Stephanie J Lee; Blair H Floyd; Despina Litsa; Sankari Arumugarajah; Roberto Bellucci; Edwin P Alyea; Joseph H Antin; Robert J Soiffer; Jerome Ritz
Journal:  Blood       Date:  2005-06-21       Impact factor: 22.113

9.  VASCULAR INFLAMMATION AND ATHEROGENESIS ARE ACTIVATED VIA RECEPTORS FOR PAMPs AND SUPPRESSED BY REGULATORY T CELLS.

Authors:  Xiao-Feng Yang; Ying Yin; Hong Wang
Journal:  Drug Discov Today Ther Strateg       Date:  2008

Review 10.  Immunotherapy of malignant brain tumors.

Authors:  Duane A Mitchell; Peter E Fecci; John H Sampson
Journal:  Immunol Rev       Date:  2008-04       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.